Spark Therapeutics Inc. (NASDAQ:ONCE) shares were down 5.1% on Monday . The company traded as low as $50.52 and last traded at $51.91, with a volume of 298,859 shares. The stock had previously closed at $54.68.

A number of research analysts recently weighed in on ONCE shares. Zacks Investment Research raised Spark Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a report on Wednesday, April 20th. Evercore ISI started coverage on Spark Therapeutics in a report on Tuesday, April 12th. They set a “buy” rating and a $37.00 price objective on the stock. Cowen and Company reaffirmed a “buy” rating and set a $75.00 price objective on shares of Spark Therapeutics in a report on Wednesday, May 4th. Cantor Fitzgerald started coverage on Spark Therapeutics in a report on Thursday, June 2nd. They set a “buy” rating and a $100.00 price objective on the stock. Finally, SunTrust Banks Inc. upped their price objective on Spark Therapeutics from $64.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, June 21st. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $58.70.

The firm has a 50-day moving average of $51.33 and a 200-day moving average of $39.01. The firm’s market cap is $1.47 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.95) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.11. The company had revenue of $1.29 million for the quarter, compared to analyst estimates of $1.48 million. Spark Therapeutics’s revenue was down 43.2% on a year-over-year basis. Analysts predict that Spark Therapeutics Inc. will post ($3.81) EPS for the current fiscal year.

In other news, insider Coelho Rogerio Vivaldi sold 7,000 shares of the firm’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $53.03, for a total value of $371,210.00. Following the completion of the transaction, the insider now owns 19,716 shares in the company, valued at approximately $1,045,539.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Hospital Of Philade Children’s sold 1,000,000 shares of the firm’s stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $42.30, for a total value of $42,300,000.00. Following the completion of the transaction, the insider now owns 6,768,707 shares of the company’s stock, valued at approximately $286,316,306.10. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Spark Therapeutics stock. TD Asset Management Inc. increased its stake in shares of Spark Therapeutics Inc. (NASDAQ:ONCE) by 72.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 58,187 shares of the company’s stock after buying an additional 24,400 shares during the period. TD Asset Management Inc. owned 0.24% of Spark Therapeutics worth $2,636,000 as of its most recent filing with the SEC.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.